Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

When LRM is given to HIV patients, it prevents HIV

Message Board Public Reply | Private Reply | Keep | Replies (2)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 153798
(Total Views: 528)
Posted On: 07/03/2022 12:10:36 PM
Posted By: MGK_2
Re: sean007 #125888
When LRM is given to HIV patients, it prevents HIV from entering the CD-4 T Lymphocyte. It acts as an entry inhibitor. It does not keep it in a holding cell. It doesn't "go after' dormant HIV within CD-4 T Lymphocytes. All it does is prevent HIV from entering.

This Reservoir occurs not just in LRM treated patients, but in HAART treated patients as well. The HIV virus enters the CD 4 T Lymphocyte and then goes dormant for years and years. Finally, to emerge years later once HAART therapy is stopped or postponed. Thereby re-introducing the same disease process.

It is the virus' way of never being eradicated from a person's body once infected.

That is why they want to develop the HIV cure using AAV vector, Adeno Associated Virus Vector. Scott Kelly describes it here:

Quote:
Now, as Antonio mentioned, we do have some exciting news to announce regarding an NIH grant for HIV cure. We will be announcing this shortly, but OSHU has received ~$5 million grant from NIH to evaluate the role of LRM in HIV cure. The project director is Dr. Jonas Sacha. As you are aware, only 3 people have ever been cured of HIV and they received immune cells void of CCR5 receptor which is the same receptor that LRM blocks. What is unique about this grant, centers around the technology. We'll will be using a AAV vector (adeno associated virus vector), which delivers a gene encoded LRM into immune cells. Adenovirus is a promising vector platform due to safety and ability to stimulate immune responses in multiple species. This is essentially, a gene therapy designed to induce the body to produce LRM. If successful, this work could lead to a single injection that suppresses HIV replication long term without needing ART and this is one of the many projects we are working on to obtain non-dilutive capital financing of trials. We will keep you up to date as these progress.



So if a patient has HIV, he has already developed antibodies to HIV. The body will try to reduce viral load on its own, but, in the end would be unsuccessful. The HIV virus will always win. Regardless, antibodies against it are in the patients memory. The HIV virus will go dormant while on HAART or LRM, but when the treatment stops, the HIV will re-emerge.

Now, it this patient receives the AAV vector treatment and the patient becomes capable of producing LRM within his own metabolism, if the HIV dormant virus, again becomes active and reproduces with in the CD-4T lymphocyte, and causes that cell to apoptosis, thereby spilling many HIV into the blood stream, it becomes impossible for those to enter any more CD-4 T lymphocytes because the body is now manufacturing its own LRM. And those free floating HIV progeny of the dormant HIV will be eliminated by the patient's antibodies and T memory cells.

It is possible, that with the patient's manufacture of LRM, this alone will suppress or prevent the dormant HIV from becoming activated, but if they do, their HIV progeny will be unsuccessful in entering any more cells due to the LRM already being produced by the patient's own metabolism, as encoded in their DNA by the AAV vector. So either the dormant HIV will remain dormant for life due to the presence of self manufactured LRM or if they decide to venture out and become active, they would then cause their host cell to apoptosis releasing their progeny into the blood leaving them susceptible to existing antibodies and T-memory cells and they also would be prevented from entering CD-4 T cells as well.


(4)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us